An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis
Top Cited Papers
Open Access
- 1 June 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (6) , 719-727
- https://doi.org/10.1001/archderm.139.6.719
Abstract
PSORIASIS IS a chronic, inflammatory, hyperproliferative skin disorder estimated to affect up to 2.5% of the world's population.1 Patients with psoriasis have a range of psychosocial difficulties and stresses commensurate with their physically disfiguring condition.2 This psychosocial aspect of the disease is consistently underestimated and often results in suboptimal care and reduced quality of life.3-5Keywords
This publication has 26 references indexed in Scilit:
- Biologic therapies in dermatologyBritish Journal of Hospital Medicine, 2013
- The immune system.Published by CABI Publishing ,2010
- The immunologic basis for the treatment of psoriasis with new biologic agentsJournal of the American Academy of Dermatology, 2002
- Therapeutic strategies for psoriasisJournal of Clinical Pharmacy & Therapeutics, 2000
- Inflammatory Skin Diseases, T Cells, and Immune SurveillanceNew England Journal of Medicine, 1999
- Psoriasis: current perspectives with an emphasis on treatmentThe American Journal of Medicine, 1999
- The pathogenesis of psoriasis: immunological facts and speculationsPublished by Elsevier ,1999
- Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+T cells is independent of cell activationCell Adhesion and Communication, 1999
- Assessing illness-related stress in psoriasis: The psychometric properties of the Psoriasis Life Stress InventoryJournal of Psychosomatic Research, 1997
- Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.The Journal of Experimental Medicine, 1993